Novanta Posts 3Q Adjusted EPS of $1.05
NOVT sits 49% above its 52-week low of $98.27.
Summary
Novanta reported third-quarter adjusted EPS of $1.05 and 3Q EPS of 5c. The headline carries only the adjusted EPS figure — no revenue, GAAP earnings, or guidance was disclosed in the item, so the comparison to consensus is not determinable from this report alone. Context matters here: the company closed the $1.45 billion Riverpoint Medical acquisition in July, funded with $616M of new debt and cash, and filed the required Riverpoint financials in an 8-K/A on October 2 that revealed a $250 million item. Those deal-related charges and the added interest burden make adjusted versus GAAP earnings a key distinction this quarter. Q2 2026 revenue was $265.8M (+10.3% YoY) with diluted EPS of $0.30, so this print is the first full quarter reflecting Riverpoint.
At the time of this announcement, NOVT was trading at $146.00 on NASDAQ in the Technology sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $98.27 to $176.38. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.